Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3423
| Subject | Predicate | Object | Context |
|---|---|---|---|
| dailymed-drugs:3423 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3423 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:3423 | rdfs:label | Sucralfate (Tablet) | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:dosage | Active Duodenal Ulcer: The recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach. Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.<br/>Maintenance Therapy: The recommended adult oral dosage is 1 g twice a day.<br/>Elderly: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS, Geriatric Use.) | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:descripti... | Sucralfate is an��-D-glucopyranoside,��-D-fructofuranosyl-, octakis(hydrogen sulfate), aluminum complex. R=SO[Al(OH)��(HO)] Tablets for oral administration contain 1 g of sucralfate.<br/>Inactive Ingredients: Corn starch, magnesium stearate, and microcrystalline cellulose<br/>Therapeutic Category: antiulcer | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:clinicalP... | Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent: These observations suggest that sucralfate's antiulcer activity is the result of formation of an ulcer-adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14-16 mEq of acid-neutralizing capacity per 1 g dose of sucralfate. | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:activeIng... | dailymed-ingredient:Sucralf... | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:contraind... | There are no known contraindications to the use of sucralfate. | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:supply | Sucralfate tablets, USP are supplied as white, single-scored, capsule-shaped tablets containing 1 gram of sucralfate. Available in bottles of 100 and 500. Tablets are debossed���BIOCRAFT���on one side and���105���twice on the scored side. Store at 20��to 25��C (68��to 77��F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Manufactured By: TEVA PHARMACEUTICALS USA Sellersville, PA 18960 Rev. E 5/2007 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:genericDr... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:activeMoi... | dailymed-ingredient:Sucralf... | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:inactiveI... | dailymed-ingredient:corn_st... | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:inactiveI... | dailymed-ingredient:magnesi... | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:inactiveI... | dailymed-ingredient:microcr... | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:81 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:338 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:1436 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:2198 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:46 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:79 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:342 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:576 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:1130 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:1358 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:1359 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:1427 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:2202 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:2203 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:2204 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:2205 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:2730 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:4046 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:possibleD... | diseasome-diseases:4047 | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:precautio... | Duodenal ulcer is a chronic, recurrent disease. While short-term treatment with sucralfate can result in complete healing of the ulcer, a successful course of treatment with sucralfate should not be expected to alter the posthealing frequency or severity of duodenal ulceration.<br/>Special Populations:<br/>Chronic Renal Failure and Dialysis Patients: When sucralfate is administered orally, small amounts of aluminum are absorbed from the gastrointestinal tract. Concomitant use of sucralfate with other products that contain aluminum, such as aluminum-containing antacids, may increase the total body burden of aluminum. Patients with normal renal function receiving the recommended doses of sucralfate and aluminum-containing products adequately excrete aluminum in the urine. Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum. In addition, aluminum does not cross dialysis membranes because it is bound to albumin and transferrin plasma proteins. Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy) have been described in patients with renalimpairment. Sucralfate should be used with caution in patients with chronic renal failure.<br/>Drug Interactions: Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, 1-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy. The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. In all case studies to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. Because of the potential of sucralfate to alter the absorption of some drugs, sucralfate should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately.<br/>Carcinogenesis, Mutagenesis, Impairment of Fertility: Chronic oral toxicity studies of 24 months' duration were conducted in mice and rats at doses up to 1 g/kg (12 times the human dose). There was no evidence of drug-related tumorigenicity. A reproduction study in rats at doses up to 38 times the human dose did not reveal any indication of fertility impairment. Mutagenicity studies were not conducted.<br/>Pregnancy:<br/>Teratogenic Effects:<br/>Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sucralfate is administered to a nursing woman.<br/>Pediatric Use: Safety and effectiveness in children have not been established.<br/>Geriatric Use: Clinical studies of sucralfate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See DOSAGE AND ADMINISTRATION.) This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. (See PRECAUTIONS, Special Populations, Chronic Renal Failure and Dialysis Patients.) Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:overdosag... | Due to limited experience in humans with overdosage of sucralfate, no specific treatment recommendations can be given. Acute oral toxicity studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose. Sucralfate is only minimally absorbed from the gastrointestinal tract. Risks associated with acute overdosage should, therefore, be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic. Those few reports where adverse events were described included symptoms of dyspepsia, abdominal pain, nausea, and vomiting. | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:genericMe... | Sucralfate | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:fullName | Sucralfate (Tablet) | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:adverseRe... | Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system:<br/>Gastrointestinal: diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth<br/>Dermatological: pruritus, rash<br/>Nervous System: dizziness, insomnia, sleepiness, vertigo<br/>Other: back pain, headache Postmarketing reports of hypersensitivity reactions, including urticaria (hives), angioedema, respiratory difficulty, rhinitis, laryngospasm, and facial swelling have been reported in patients receiving sucralfate tablets. Similar events were reported with sucralfate suspension. However, a causal relationship has not been established. Bezoars have been reported in patients treated with sucralfate. The majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. Inadvertent injection of insoluble sucralfate and its insoluble excipients has led to fatal complications, including pulmonary and cerebral emboli. Sucralfate is not intended for intravenous administration. | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:indicatio... | Sucralfate is indicated in: | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:3423 | dailymed-instance:name | Sucralfate | lld:dailymed |
| http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:3423 | lld:dailymed |
| diseasome-diseases:81 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:338 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:1436 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:2198 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:46 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:79 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:342 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:576 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:1130 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:1358 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:1359 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:1427 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:2202 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:2203 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:2204 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:2205 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:2730 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:4046 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |
| diseasome-diseases:4047 | diseasome-instance:possible... | dailymed-drugs:3423 | lld:diseasome |